Remove Diagnostic Imaging Remove Events Remove Radiation Remove Radiation Oncology
article thumbnail

The rise of theranostics: Part 5 -- Advice from center administrators

AuntMinnie

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Involve radiation safety early in your therapy center development. "If The bottom line?

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.

article thumbnail

AuntMinnie 2011: Joint Commission issues alert on medical radiation

AuntMinnie

Joint Commission on the dangers of medical radiation. Joint Commission has issued an alert on the dangers of medical radiation, sending an unmistakable signal that radiology has entered its sights in a formal way. New articles will be published each Monday until our official anniversary at RSNA 2024. Noting that the U.S.

article thumbnail

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Chief Executive Officer of Blue Earth Diagnostics. Of the identified lesions, 16-25 were successfully verified (predominantly using follow-up imaging as SoT) as TP, providing a M1 VDR of 8.1-13%,